ArticleBMC surgery2026
Efficacy of uterine artery ascending branch ligation for preventing postpartum hemorrhage in Caesarean section for placenta previa.
Article in BMC surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPostpartum hemorrhage (PPH) remains a leading cause of maternal morbidity and mortality globally. This study aimed to assess the efficacy of ascending uterine artery ligation (AUAL) in preventing PPH among patients undergoing cesarean section (CS) for placenta previa.
methodsA retrospective cohort study was conducted at our institution between January 2022 and December 2024, enrolling 103 patients with placenta previa who underwent CS with concurrent AUAL. A matched control group was included, comprising 134 patients with placenta previa who underwent CS with administration of specialized uterotonic agents (without AUAL). All participants in both groups received intraoperative and postoperative oxytocin administration. Demographic characteristics and clinical outcomes were compared between the two groups, including maternal age, gestational age at delivery, parity, total surgical duration, 24-hour postpartum blood loss volume, postoperative hemoglobin concentration, occurrence of puerperal fever, and rate of uterine involution. Postoperative abdominal pain intensity was assessed via the Numerical Rating Scale (NRS).
resultsNo statistically significant differences were observed between the AUAL group and the control group regarding maternal age, gestational age at delivery, parity, uterine involution rate, or the incidence of puerperal fever (P > 0.05). Notably, the AUAL group had significantly lower total 24-hour postpartum blood loss (495.3 ± 159.9 ml vs. 648.1 ± 246.8 ml, P < 0.001) and a smaller reduction in postoperative hemoglobin (12.8 ± 5.5 g/L vs. 16.8 ± 6.8 g/L, P < 0.001) compared with the control group. However, the AUAL group was associated with a significantly longer operative time (1.9 ± 0.4 h vs. 1.7 ± 0.5 h, P = 0.025) and more severe postoperative abdominal pain.
conclusionsAUAL serves as an effective intervention to reduce 24‑hour postoperative blood loss in patients undergoing cesarean section for placenta previa. Although it was associated with more severe postoperative abdominal pain, it does not compromise key clinical recovery outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.